Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP +2.13% EV-to-EBIT is -1.22 as of Jul. 30, 2026. The stock has 6 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 961537.5% on this metric.
The historical rank and industry rank for Microba Life Sciences's EV-to-EBIT or its related term are showing as below:
ASX:MAP'
s EV-to-EBIT Range Over the Past 10 Years
Min: -7.24 Med: -2.47 Max: -0.17
Current: -1.22
During the past 4 years, the highest EV-to-EBIT of Microba Life Sciences was -0.17. The lowest was -7.24. And the median was -2.47.
ASX:MAP's EV-to-EBIT is ranked worse than 100% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.78
vs ASX:MAP: -1.22
Microba Life Sciences (ASX:MAP) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Microba Life Sciences's Enterprise Value for the quarter that ended in Dec. 2025 was A$37.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Microba Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's EV-to-EBIT falls into.
Microba Life Sciences's current Enterprise Value is A$24.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a EV-to-EBIT of -1.22 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry.
Is Microba Life Sciences' EV-to-EBIT too high?
Microba Life Sciences' current EV-to-EBIT is -1.22. Based on the distribution chart, Microba Life Sciences ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Microba Life Sciences' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #999999 out of 104 companies for EV-to-EBIT. This places Microba Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 22.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.78, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current EV-to-EBIT is -1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.05 — trading 79.1% below its estimated fair value. The current EV-to-EBIT is -1.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current EV-to-EBIT is -1.22 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
